Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis.
Expert Rev Clin Pharmacol
; 14(4): 457-464, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1467264
ABSTRACT
INTRODUCTION:
Galectin-3 (Gal-3) is a ß-galactoside binding protein associated with many disease pathologies, including chronic inflammation and fibrogenesis. It has been implicated in the disease severity of NASH, although its precise role is unknown. Inhibition of Gal-3 has shown to improve and prevent fibrosis progression and has now reached phase III clinical trial in NASH patients. AREAS COVERED This discusses the role of Gal-3 in NASH. It brings together the current findings of Gal-3 in NASH and hepatic fibrosis by analyzing recent data from animal model studies and clinical trials. EXPERT OPINION Gal-3 inhibitors, in particular, Belapectin (GR-MD-02), have shown promising results for NASH with advanced fibrosis. In a phase 2 trial, Belapectin did not meet the primary endpoint. However, a sub-analysis of Belapectin among a separate group of patients without esophageal varices showed 2 mg/kg of GR-MD-02 reduced HVPG and the development of new varices. A subsequent study is under way, aiming to replicate the positive findings in phase 2 and demonstrate greater efficacy. If Belapectin is shown to be effective, it will be coupled with other drugs that target steatohepatitis to maximize efficacy and disease reversal.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Blood Proteins
/
Galectins
/
Non-alcoholic Fatty Liver Disease
/
Liver Cirrhosis
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Animals
/
Humans
Language:
English
Journal:
Expert Rev Clin Pharmacol
Year:
2021
Document Type:
Article
Affiliation country:
17512433.2021.1894127
Similar
MEDLINE
...
LILACS
LIS